Skip to main content

Main menu

  • Home
  • Articles
    • Current Issue
    • Next in The JI
    • Archive
    • Brief Reviews
    • Pillars of Immunology
    • Translating Immunology
    • Most Read
    • Top Downloads
    • Annual Meeting Abstracts
  • COVID-19/SARS/MERS Articles
  • Info
    • About the Journal
    • For Authors
    • Journal Policies
    • Influence Statement
    • For Advertisers
  • Editors
  • Submit
    • Submit a Manuscript
    • Instructions for Authors
    • Journal Policies
  • Subscribe
    • Journal Subscriptions
    • Email Alerts
    • RSS Feeds
    • ImmunoCasts
  • More
    • Most Read
    • Most Cited
    • ImmunoCasts
    • AAI Disclaimer
    • Feedback
    • Help
    • Accessibility Statement
  • Other Publications
    • American Association of Immunologists
    • ImmunoHorizons

User menu

  • Subscribe
  • Log in

Search

  • Advanced search
The Journal of Immunology
  • Other Publications
    • American Association of Immunologists
    • ImmunoHorizons
  • Subscribe
  • Log in
The Journal of Immunology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Next in The JI
    • Archive
    • Brief Reviews
    • Pillars of Immunology
    • Translating Immunology
    • Most Read
    • Top Downloads
    • Annual Meeting Abstracts
  • COVID-19/SARS/MERS Articles
  • Info
    • About the Journal
    • For Authors
    • Journal Policies
    • Influence Statement
    • For Advertisers
  • Editors
  • Submit
    • Submit a Manuscript
    • Instructions for Authors
    • Journal Policies
  • Subscribe
    • Journal Subscriptions
    • Email Alerts
    • RSS Feeds
    • ImmunoCasts
  • More
    • Most Read
    • Most Cited
    • ImmunoCasts
    • AAI Disclaimer
    • Feedback
    • Help
    • Accessibility Statement
  • Follow The Journal of Immunology on Twitter
  • Follow The Journal of Immunology on RSS

The flt3 ligand promotes the survival of primitive hemopoietic progenitor cells with myeloid as well as B lymphoid potential. Suppression of apoptosis and counteraction by TNF-alpha and TGF-beta.

O P Veiby, F W Jacobsen, L Cui, S D Lyman and S E Jacobsen
J Immunol October 1, 1996, 157 (7) 2953-2960;
O P Veiby
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
F W Jacobsen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
L Cui
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S D Lyman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S E Jacobsen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

The recently cloned fIt3 ligand (FL) potently enhances hemopoietic growth factor-induced growth of primitive hemopoietic progenitors. In agreement with previous reports, we found FL alone to be a weak mitogen for primitive Lin-Sca-1+ murine bone marrow progenitors. Using delayed addition of growth-promoting cytokines, we demonstrate that FL potently promotes the in vitro survival of Lin-Sca-1+ progenitors responsive to a potent myeloid growth factor combination (FL, stem cell factor (SCF), granulocyte CSF (G-CSF), and IL-1 alpha). Whereas no such progenitors survived in cultures supplemented with medium alone, 33% survived in FL compared with 75 and 13% in the presence of SCF and IL-1 alpha, respectively. These results were obtained when cells were plated individually, suggesting that the viability-promoting effect of FL is mediated directly on the progenitors. Whereas SCF was superior to FL in promoting the survival of FL-, SCF-, G-CSF-, and IL-1 alpha-stimulated Lin-Sca-1+ progenitors, FL was more efficient than SCF at promoting the survival of progenitors with a B cell potential, as measured by their ability to produce B220+ cells in response to delayed addition of FL, SCF, and IL-7. Seventy-one percent of the B220+ cell production could be recovered following 40-h incubation with FL compared with 2% in response to SCF. Analysis of day 12 spleen CFU content after 40-h preincubation of Lin-Sca-1+ cells in FL or SCF demonstrated that SCF maintained 64% of the day 12 spleen CFU, whereas only 16% survived in the presence of FL. Finally, there was no significant difference between the ability of FL and SCF to maintain the viability of long-term culture-initiating cells (25 and 32%, respectively). The ability of FL to promote the survival of Lin-Sca-1+ progenitor cells was reflected by the finding that FL also suppressed apoptosis. Finally, TGF-beta abrogated and TNF-alpha potently counteracted the survival-promoting effect of FL. Thus, FL promotes the survival of primitive hemopoietic progenitor cells, in particular those with an inherent B lymphoid potential.

  • Copyright © 1996 by American Association of Immunologists

Pay Per Article - You may access this article (from the computer you are currently using) for 1 day for US$37.50

Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.

Log in using your username and password

Forgot your user name or password?
PreviousNext
Back to top

In this issue

The Journal of Immunology
Vol. 157, Issue 7
1 Oct 1996
  • Table of Contents
  • Table of Contents (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Immunology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The flt3 ligand promotes the survival of primitive hemopoietic progenitor cells with myeloid as well as B lymphoid potential. Suppression of apoptosis and counteraction by TNF-alpha and TGF-beta.
(Your Name) has forwarded a page to you from The Journal of Immunology
(Your Name) thought you would like to see this page from the The Journal of Immunology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
The flt3 ligand promotes the survival of primitive hemopoietic progenitor cells with myeloid as well as B lymphoid potential. Suppression of apoptosis and counteraction by TNF-alpha and TGF-beta.
O P Veiby, F W Jacobsen, L Cui, S D Lyman, S E Jacobsen
The Journal of Immunology October 1, 1996, 157 (7) 2953-2960;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
The flt3 ligand promotes the survival of primitive hemopoietic progenitor cells with myeloid as well as B lymphoid potential. Suppression of apoptosis and counteraction by TNF-alpha and TGF-beta.
O P Veiby, F W Jacobsen, L Cui, S D Lyman, S E Jacobsen
The Journal of Immunology October 1, 1996, 157 (7) 2953-2960;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

Cited By...

Similar Articles

Navigate

  • Home
  • Current Issue
  • Next in The JI
  • Archive
  • Brief Reviews
  • Pillars of Immunology
  • Translating Immunology

For Authors

  • Submit a Manuscript
  • Instructions for Authors
  • About the Journal
  • Journal Policies
  • Editors

General Information

  • Advertisers
  • Subscribers
  • Rights and Permissions
  • Accessibility Statement
  • FAR 889
  • Privacy Policy
  • Disclaimer

Journal Services

  • Email Alerts
  • RSS Feeds
  • ImmunoCasts
  • Twitter

Copyright © 2022 by The American Association of Immunologists, Inc.

Print ISSN 0022-1767        Online ISSN 1550-6606